call 1800 257 600 email [email protected]

Clinical Trials

Cancer Type

State

Phase

Treatment

Inhibitor

Safety and Efficacy of NOX66 in combination with Nivolumab for patients with solid tumours – a pilot study (IONIC-1).

ACTRN 12621001537842 Brief Summary This trial aims to determine whether NOX66 (idronoxil)…

Read more arrow_forward

Single arm, open label, signal seeking, phase II trial of the activity of tucatinib plus trastuzumab in patients with tumours harbouring HER2 amplifications or mutations

ACTRN 12620000767909 Brief Summary This is a substudy of the Cancer Molecular…

Read more arrow_forward

Single-institution, single-arm, open-label phase II basket study of mutation and/or elevated hedgehog (Hh) expression-directed smoothened inhibitor sonidegib in patients with advanced solid malignancies

ACTRN 12623001216606 Brief Summary The purpose of the study is to investigate…

Read more arrow_forward

Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors (DOMISOL)

NCT 06819735 Brief Summary This is a phase 1/2, dose-escalation and cohort-expansion…

Read more arrow_forward

Knowledgebase

Cancer Types Cancer Services Health Professionals

How we help you

Our support knows no limits, which means we do whatever it takes to be there for all you need.

How we help you View the Rare Cancer Support Guide

Can’t find what you’re looking for?

We have a friendly team available to chat about any questions you may have, or just to lend an ear if you’re having a tough time.

Call 1800 257 600 Have us call you

Need an interpreter?

Now it's personal: Access and equity for all

Refer a patient

Make a donation

Contact us

Find my...

How we help you

Information & Support

Personal Stories

The Reality of Rare

Advocacy

Optimal Care Pathway (OCP)

Media releases

Supporting your patient

Resources

Education Hub

Our Programs

Ways to give

Fundraise

Volunteer

Partner

Our Story

Our Team

Our Programs

Resources

Clinical Trials

Safety and Efficacy of NOX66 in combination with Nivolumab for patients with solid tumours – a pilot study (IONIC-1).

Single arm, open label, signal seeking, phase II trial of the activity of tucatinib plus trastuzumab in patients with tumours harbouring HER2 amplifications or mutations

Single-institution, single-arm, open-label phase II basket study of mutation and/or elevated hedgehog (Hh) expression-directed smoothened inhibitor sonidegib in patients with advanced solid malignancies

Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors (DOMISOL)